NO20023829L - Proteosom influensavaksine - Google Patents

Proteosom influensavaksine

Info

Publication number: NO20023829L
Authority: NO; Norway
Prior art keywords: influenza vaccine; vaccines; proteosome; proteosome influenza; proteosomes
Prior art date: 2000-02-15

Application number

NO20023829A

Other languages

English (en)

Other versions

NO20023829D0 (no

Inventor

David S Burt

Gregory Lee White

Iii Louis F Fries

Kirkor Torossian

David Hugh Jones

Martin Plante

George H Lowell

Original Assignee

Id Biomedical Corp Quebec

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2002-08-13

Publication date

2002-08-13

2002-08-13 Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec

2002-08-13 Publication of NO20023829L publication Critical patent/NO20023829L/no

2002-08-13 Publication of NO20023829D0 publication Critical patent/NO20023829D0/no

Links

229960003971 influenza vaccine Drugs 0.000 title 1
229960005486 vaccine Drugs 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
206010022000 influenza Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO20023829A 2000-02-15 2002-08-13 Proteosom influensavaksine NO20023829D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18247600P	2000-02-15	2000-02-15
PCT/US2001/005222 WO2001060402A2 (en)	2000-02-15	2001-02-15	Proteosome influenza vaccine

Publications (2)

Publication Number	Publication Date
NO20023829L true NO20023829L (no)	2002-08-13
NO20023829D0 NO20023829D0 (no)	2002-08-13

Family

ID=22668645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023829A NO20023829D0 (no)	2000-02-15	2002-08-13	Proteosom influensavaksine

Country Status (11)

Country	Link
US (3)	US6743900B2 (no)
EP (1)	EP1255561B1 (no)
JP (2)	JP3980884B2 (no)
AT (1)	ATE331530T1 (no)
AU (4)	AU2001238478C1 (no)
CA (1)	CA2400468C (no)
DE (1)	DE60121136T2 (no)
ES (1)	ES2267724T3 (no)
IL (2)	IL150602A0 (no)
NO (1)	NO20023829D0 (no)
WO (1)	WO2001060402A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL123720A (en) *	1995-09-18	2002-02-10	Us Army Medical Res Material C	Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2001060402A2 (en) *	2000-02-15	2001-08-23	Intellivax International Inc.	Proteosome influenza vaccine
DE60238471D1 (de) *	2001-03-09	2011-01-13	Id Biomedical Corp Quebec	Proteosom-liposaccharid-vakzine-adjuvans
CN1607941A (zh)	2001-11-19	2005-04-20	贝克顿迪肯森公司	粒状药物组合物
NZ536859A (en) *	2002-05-14	2007-11-30	Chiron Srl	Mucosal combination vaccines for bacterial meningitis
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
EP1578443B1 (en) *	2002-11-20	2011-01-12	Bestewil Holding B.V.	Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination
US7491395B2 (en)	2002-11-20	2009-02-17	Bestewil Holding B.V.	Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP1447080A1 (en)	2003-02-13	2004-08-18	Bestewil Holding B.V.	Method for producing virosome-like particles
TWI329130B (en) *	2003-06-19	2010-08-21	Bestewil Holding Bv	Functionally reconstituted viral membranes containing adjuvant
US7368537B2 (en)	2003-07-15	2008-05-06	Id Biomedical Corporation Of Quebec	Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) *	2003-09-15	2007-03-15	アイディーバイオメディカルコーポレイションオブケベック	麻疹サブユニットワクチン
GB0323231D0 (en) *	2003-10-03	2003-11-05	Chiron Srl	Immunodiffusion assays
ATE472336T1 (de)	2003-10-22	2010-07-15	Id Biomedical Corp Quebec	Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
CA2571035A1 (en) *	2004-06-25	2006-01-12	Id Biomedical Corporation Of Quebec	Compositions and methods for treating neurological disorders
JP2008505114A (ja) *	2004-06-30	2008-02-21	アイディーバイオメディカルコーポレイションオブケベック	コロナウイルス感染を処置するためのワクチン組成物
CN101189030A (zh) *	2005-06-02	2008-05-28	阿尔扎公司	透皮递送器械的最终消毒方法
US8535683B2 (en) *	2006-03-22	2013-09-17	Abbott Biologicals B.V.	Intranasal or inhalational administration of virosomes
US20080038294A1 (en) *	2006-03-22	2008-02-14	Kersten Alexander J	Intranasal or inhalational administration of virosomes
WO2008073490A1 (en) *	2006-12-12	2008-06-19	Carrington Laboratories Inc.,	Purification of influenza viral antigens
BRPI0809435A2 (pt)	2007-03-27	2014-09-09	Sea Lane Biotechnologies, Llc	Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
WO2009115917A2 (en) *	2008-03-18	2009-09-24	Novartis Ag	Improvements in preparation of influenza virus vaccine antigens
WO2009121004A2 (en)	2008-03-28	2009-10-01	Sea Lane Biotechnologies, Llc	Neutralizing molecules to viral antigens
KR100966566B1 (ko)	2009-01-29	2010-06-29	엘지전자 주식회사	효율적인 공용 ｅ-ｄｃｈ 관리를 위한 신호 전송 기법
CN102482345A (zh)	2009-05-13	2012-05-30	航道生物技术有限责任公司	针对流感病毒的中和分子
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
US9907746B2 (en)	2009-07-06	2018-03-06	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en)	2009-07-06	2015-06-04	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
WO2011106525A2 (en)	2010-02-26	2011-09-01	The Brigham And Women's Hospital, Inc.	Methods of treating cerebral amyloid angiopathy
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
MX342138B (es)	2010-07-06	2016-09-14	Variation Biotechnologies Inc	Composiciones y metodos para el tratamiento de influenza.
CA2862864C (en)	2011-01-13	2018-12-11	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
CA2862871C (en)	2011-01-13	2020-09-22	Variation Biotechnologies Inc.	Methods for preparing vesicles and formulations produced therefrom
WO2013016714A1 (en)	2011-07-28	2013-01-31	Sea Lane Biotechnologies	Sur-binding proteins against erbb3
US20140328876A1 (en)	2011-11-18	2014-11-06	Variation Biotechnologies Inc.	Synthetic derivatives of mpl and uses thereof
EP3446707A1 (en)	2011-12-22	2019-02-27	i2 Pharmaceuticals, Inc.	Surrogate binding proteins
US20140356399A1 (en)	2012-01-12	2014-12-04	Variation Biotechnologies, Inc.	Compositions and methods for treating viral infections
US20150079077A1 (en)	2012-01-27	2015-03-19	Variation Biotechnologies, Inc.	Methods and compositions for therapeutic agents
KR101601393B1 (ko)	2014-02-20	2016-03-09	현대자동차주식회사	차량용 비상 버튼
KR102482744B1 (ko)	2016-11-04	2022-12-30	다케다 야쿠힌 고교 가부시키가이샤	아데노-연관 바이러스 정제 방법
WO2019035972A1 (en) *	2017-08-16	2019-02-21	Georgia State University Research Foundation, Inc.	SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
WO2022152939A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707543A (en)	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en)	1987-06-23	1998-03-10	Lowell; George H.	Immuno-potentiating systems for preparation of immunogenic materials
DE3830496C1 (de) *	1988-09-08	1996-09-19	Daimler Benz Aerospace Ag	Vorrichtung zum Erkennen und Verfolgen von Objekten
SK279209B6 (sk) *	1992-12-21	1998-08-05	Virologický Ústav Sav	Bivalentné imunogény a spôsob ich prípravy
US5576016A (en)	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en)	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en)	1993-10-29	1995-05-04	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
IL123720A (en) *	1995-09-18	2002-02-10	Us Army Medical Res Material C	Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
ES1032221Y (es) *	1995-10-04	1996-11-01	Ferre Jose Manuel Rodriguez	Tobogan componible perfeccionado para uso infantil.
EP0929678A2 (en) *	1996-07-10	1999-07-21	ID Biomedical Corporation of Maryland	Protein and peptide vaccines for inducing mucosal immunity
JP3426177B2 (ja) *	1999-12-28	2003-07-14	明智セラミックス株式会社	鋳造用ストッパー
WO2001060402A2 (en) *	2000-02-15	2001-08-23	Intellivax International Inc.	Proteosome influenza vaccine
US6726292B1 (en) *	2000-07-27	2004-04-27	Daimlerchrysler Corporation	Full off-set two-piece fiber reinforced composite wheel using spoke or web area box sections

2001
- 2001-02-15 WO PCT/US2001/005222 patent/WO2001060402A2/en not_active Ceased
- 2001-02-15 ES ES01910923T patent/ES2267724T3/es not_active Expired - Lifetime
- 2001-02-15 JP JP2001559498A patent/JP3980884B2/ja not_active Expired - Lifetime
- 2001-02-15 US US09/788,280 patent/US6743900B2/en not_active Expired - Lifetime
- 2001-02-15 AT AT01910923T patent/ATE331530T1/de not_active IP Right Cessation
- 2001-02-15 IL IL15060201A patent/IL150602A0/xx unknown
- 2001-02-15 DE DE60121136T patent/DE60121136T2/de not_active Expired - Lifetime
- 2001-02-15 EP EP01910923A patent/EP1255561B1/en not_active Expired - Lifetime
- 2001-02-15 AU AU2001238478A patent/AU2001238478C1/en not_active Expired
- 2001-02-15 AU AU3847801A patent/AU3847801A/xx active Pending
- 2001-02-15 CA CA2400468A patent/CA2400468C/en not_active Expired - Lifetime
2002
- 2002-07-04 IL IL150602A patent/IL150602A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023829A patent/NO20023829D0/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/771,737 patent/US7399840B2/en not_active Expired - Lifetime
2006
- 2006-05-12 AU AU2006202003A patent/AU2006202003A1/en not_active Abandoned
- 2006-10-30 JP JP2006294115A patent/JP2007051157A/ja active Pending
2008
- 2008-06-24 US US12/144,722 patent/US20080260781A1/en not_active Abandoned
2009
- 2009-04-27 AU AU2009201657A patent/AU2009201657A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL150602A0 (en)	2003-02-12
ES2267724T3 (es)	2007-03-16
AU2001238478C1 (en)	2006-11-09
EP1255561A2 (en)	2002-11-13
CA2400468C (en)	2012-12-18
NO20023829D0 (no)	2002-08-13
IL150602A (en)	2010-12-30
US7399840B2 (en)	2008-07-15
US20080260781A1 (en)	2008-10-23
US6743900B2 (en)	2004-06-01
WO2001060402A3 (en)	2002-03-21
JP2003522802A (ja)	2003-07-29
ATE331530T1 (de)	2006-07-15
AU3847801A (en)	2001-08-27
WO2001060402A2 (en)	2001-08-23
DE60121136D1 (de)	2006-08-10
CA2400468A1 (en)	2001-08-23
HK1052629A1 (en)	2003-09-26
US20040156867A1 (en)	2004-08-12
AU2001238478B2 (en)	2006-06-01
US20010053368A1 (en)	2001-12-20
JP2007051157A (ja)	2007-03-01
JP3980884B2 (ja)	2007-09-26
DE60121136T2 (de)	2007-06-06
EP1255561B1 (en)	2006-06-28
AU2009201657A1 (en)	2009-05-21
AU2006202003A1 (en)	2006-06-01

Legal Events

Date	Code	Title	Description
2011-07-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20023829L (no)	2002-08-13	Proteosom influensavaksine
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
ATE350057T1 (de)	2007-01-15	Impfstoffzusammesetzung
CY1110585T1 (el)	2015-04-29	ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
AR014182A1 (es)	2001-02-07	Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
MY126588A (en)	2006-10-31	Intranasal influenza virus vaccine
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
NO20015073D0 (no)	2001-10-18	Vaksiner
DE60144240D1 (de)	2011-04-28	Zusammensetzung mit immunogenen mikroteilchen
MXPA05009580A (es)	2005-10-19	Vacuna contra el virus de la influenza.
DK1259259T3 (da)	2011-08-01	Mucosal adjuvansformulering
BR0010711A (pt)	2002-02-13	Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
ATE343375T1 (de)	2006-11-15	Impfstoff zur modulation zwischen t1 und t2 immunantworten
WO2002036160A3 (es)	2003-05-30	Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
DE69637435D1 (de)	2008-03-27	Saponin-zusammensetzungen und deren verwendung
AR020852A1 (es)	2002-05-29	Antigenos de vacuna de leptospira para la prevencion de leptospirosis
EP1721618A3 (en)	2007-01-10	Proteosome influenza vaccine composition
ATE353226T1 (de)	2007-02-15	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2002030458A8 (en)	2002-07-18	Yersinia adhesion protein as vaccine adjuvant
DK1490100T3 (da)	2012-03-12	Kombinerede DNA/proteinvaccinepræparater
AR037908A1 (es)	2004-12-22	Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus
WO2002072622A3 (en)	2003-04-17	Vaccine antigens against infection by chlamydia trachomatis
WO2005030802A3 (en)	2005-09-09	Antigens for an east coast fever vaccine